Transformation of MDS/MPN‐RS‐T to AML: Trisomy 13, resistant thrombocytosis and transient disease control with oral busulfan therapy

Barrett Aisling; Catherwood Mark; Thornton Patrick; Murphy Philip; Quinn John

首页> 外文期刊>American Journal of Hematology >Transformation of MDS/MPN‐RS‐T to AML: Trisomy 13, resistant thrombocytosis and transient disease control with oral busulfan therapy

【24h】

Transformation of MDS/MPN‐RS‐T to AML: Trisomy 13, resistant thrombocytosis and transient disease control with oral busulfan therapy

机译：MDS / MPN-RS-T转化为AML：三元13，抗性血小伤症和口腔血管植物治疗的抗病性

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《American Journal of Hematology》 |2018年第1期|共2页
作者
Barrett Aisling; Catherwood Mark; Thornton Patrick; Murphy Philip; Quinn John;
展开▼
作者单位

Department of HematologyBeaumont HospitalDublin Ireland;

Department of Hemato‐OncologyBelfast City HospitalBelfast United Kingdom;

Department of HematologyBeaumont HospitalDublin Ireland;

Department of HematologyBeaumont HospitalDublin Ireland;

Department of HematologyBeaumont HospitalDublin Ireland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
专利

1. Transformation of MDS/MPN‐RS‐T to AML: Trisomy 13, resistant thrombocytosis and transient disease control with oral busulfan therapy [J] . Barrett Aisling, Catherwood Mark, Thornton Patrick, American Journal of Hematology . 2018,第1期

机译：MDS / MPN-RS-T转化为AML：三元13，抗性血小伤症和口腔血管植物治疗的抗病性
2. Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML. [J] . Scott B, Deeg HJ, Storer B, Leukemia and lymphoma . 2004,第12期

机译：与目标硫醚和TBI相比，靶向目标硫醚和环磷酰胺可作为晚期MDS或向AML转化的患者的移植准备方案。
3. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. [J] . Andersson BS, de-Lima M, Thall PF, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2008,第6期

机译：每天一次白消安和氟达拉滨（Bu-Flu静脉注射）比静脉注射更有利。白消安和环磷酰胺（i.v. BuCy2）作为AML / MDS中的移植前调节疗法。
4. Effects of an Oral Nutraceutical on Clinical Aspects of Joint Disease in a Blinded, Controlled Clinical Trial: 39 Horses [C] . Kevin G. Keegan, Faith E. Hughes, Tom Lane, Annual Convention of the American Association of Equine Practitioners . 2007

机译：口腔营养法对盲，受控临床试验中联合疾病临床方面的影响：39马
5. Oral Combination Therapy Dosage Forms for Improved Response in Resistant Non-Small Cell Lung Cancers [D] . Nottingham, Ebony. 2020

机译：口腔组合治疗剂型改善抗性非小细胞肺癌的响应
6. Once Daily IV Busulfan and Fludarabine (IV Bu-Flu) Compares Favorably with IV Busulfan and Cyclophosphamide (IV BuCy2) as Pretransplant Conditioning Therapy in AML/MDS [O] . Borje S. Andersson, Marcos de Lima, Peter F. Thall, -1

机译：每日一次静脉使用白消安和氟达拉滨（IV Bu-Flu）优于静脉注射白消安和环磷酰胺（IV BuCy2）作为AML / MDS中的移植前条件治疗
7. Transformation of MDS/MPN-RS-T to AML: Trisomy 13, resistant thrombocytosis and transient disease control with oral busulfan therapy [O] . Aisling Barrett, Mark Catherwood, Patrick Thornton, 2017

机译：MDS / MPN-RS-T的转化为AML：三元13，口服血管疗法的抗性血小伤症和瞬时疾病对照
8. Manual de Adiestramiento Sobre Terapia de Rehidratacion Oral y Control de las Enfermedades Diarreicas, (Oral Rehydration Therapy and the Control of Diarrheal Diseases) [R] . Clark, M. , Harvey, M. , West, K. , 1985

机译：手册de adiestramiento sobre Terapia de Rehidratacion Oral y Control de las Enfermedades Diarreicas，（口服补液疗法和控制腹泻病）

Transformation of MDS/MPN‐RS‐T to AML: Trisomy 13, resistant thrombocytosis and transient disease control with oral busulfan therapy

著录项

引文网络

相似文献

相关主题

期刊订阅